BCBioCryst Pharmaceuticals, Inc. BCRX · NASDAQ
$7.79 -2.87% (-$0.23)
- Market cap
- $2.05B
- Enterprise value
- $2.30B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.2x
- P/FCF
- 5.7x
- EV/EBITDA
- -
- ROIC
- -89.8%
- Gross margin
- 23.5%
- Net margin
- -40.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.55
- Free float
- 86.0%
About the company
BioCryst Pharmaceuticals, Inc. (BCRX) is an American biotechnology company specializing in research, development, and commercialization of therapeutic compounds for the treatment of rare and serious diseases. With a primary focus on developing drugs for rare metabolic disorders and infections, BioCryst Pharmaceuticals leads innovations in therapeutic approaches. The company is known for its advanced technologies and successful clinical trials, which strengthen investor confidence. BioCryst Pharmaceuticals, Inc. (BCRX) shares could be suitable for investors seeking opportunities in the biotechnology sector with an emphasis on drug development for rare diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Charles K. Gayer
Employees
435
Headquarters
Durham
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number